Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

NCT01442649 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01442649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
December 31, 2017
Enrollment
133 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer